BOSUTINIB 100MG TABLETS - PC.00554.2026

Tender PC.00554.2026 is for the procurement of Bosutinib, specified as 100mg tablets. Bosutinib is a tyrosine kinase inhibitor used in the treatment of certain types of cancer, particularly Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It works by blocking the activity of specific enzymes that promote cancer cell growth. This tender indicates a requirement for this targeted cancer therapy medication for the year 2026. The procurement process will focus on ensuring the supply of high-quality, pharmaceutical-grade Bosutinib that meets all regulatory and safety standards. Key specifications will include the dosage strength (100mg), form (tablets), packaging, and required shelf-life. Bidders, typically pharmaceutical manufacturers or authorized distributors, will be evaluated based on their ability to supply the specified product, compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP), pricing, and delivery reliability. This acquisition is essential for providing effective treatment options to patients diagnosed with specific forms of leukemia.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 11,424.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.